Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
Portfolio Pulse from Vandana Singh
The FDA has approved Ascendis Pharma's (NASDAQ:ASND) Yorvipath (palopegteriparatide) for treating hypoparathyroidism in adults, making it the first and only treatment available after Takeda's (NYSE:TAK) Natpar/Natpara was discontinued due to supply issues. Ascendis plans to launch Yorvipath with patient services and anticipates initial supply availability in Q1 2025.
August 12, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Takeda's Natpar/Natpara has been discontinued due to supply issues, and Ascendis Pharma's Yorvipath has been approved as a replacement. This could negatively impact Takeda's market share in the hypoparathyroidism treatment space.
The discontinuation of Natpar/Natpara due to supply issues and the subsequent approval of Ascendis Pharma's Yorvipath is likely to negatively impact Takeda's market share in the hypoparathyroidism treatment space. This could lead to a short-term decline in Takeda's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ascendis Pharma's Yorvipath has received FDA approval for treating hypoparathyroidism, replacing Takeda's discontinued Natpar/Natpara. The stock is up 4.45% following the news.
The FDA approval of Yorvipath positions Ascendis Pharma as the sole provider of a treatment for hypoparathyroidism, a market previously served by Takeda's Natpar/Natpara. This approval is likely to drive short-term stock price appreciation due to the exclusivity and immediate market need.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100